+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Roles of the EZH2 histone methyltransferase in cancer epigenetics



Roles of the EZH2 histone methyltransferase in cancer epigenetics



Mutation Research 647(1-2): 21-29



EZH2 is the catalytic subunit of Polycomb repressive complex 2 (PRC2), which is a highly conserved histone methyltransferase that targets lysine-27 of histone H3. This methylated H3-K27 chromatin mark is commonly associated with silencing of differentiation genes in organisms ranging from plants to flies to humans. Studies on human tumors show that EZH2 is frequently over-expressed in a wide variety of cancerous tissue types, including prostate and breast. Although the mechanistic contributions of EZH2 to cancer progression are not yet determined, functional links between EZH2-mediated histone methylation and DNA methylation suggest partnership with the gene silencing machinery implicated in tumor suppressor loss. Here we review the basic molecular biology of EZH2 and the findings that implicate EZH2 in different cancers. We also discuss EZH2 connections to other silencing enzymes, such as DNA methyltransferases and histone deacetylases, and we consider progress on deciphering mechanistic consequences of EZH2 overabundance and its potential roles in tumorigenesis. Finally, we review recent findings that link EZH2 roles in stem cells and cancer, and we consider prospects for integrating EZH2 blockade into strategies for developing epigenetic therapies.

(PDF emailed within 0-6 h: $19.90)

Accession: 023547677

Download citation: RISBibTeXText

PMID: 18723033

DOI: 10.1016/j.mrfmmm.2008.07.010


Related references

Canonical and non-canonical roles of the histone methyltransferase EZH2 in mammary development and cancer. Molecular and Cellular Endocrinology 382(1): 593-597, 2014

Distinct And Separable Roles For Histone Methyltransferase Ezh2 In Neurogenic Astrocytes. Neuro-Oncology 16(suppl 3): iii17, 2014

EZH2 Histone Methyltransferase and JMJD3 Histone Demethylase Implications in Prostate Cancer. Omics 21(12): 751-753, 2017

The JMJD3 Histone Demethylase and the EZH2 Histone Methyltransferase in Prostate Cancer. Omics 20(2): 123-125, 2016

Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo. Oncotargets and Therapy 10: 3131-3144, 2017

Targeting histone methyltransferase EZH2 as cancer treatment. Journal of Biochemistry 156(5): 249-257, 2015

Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage. Oncotarget 9(12): 10585-10605, 2018

Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer. Molecular Cancer Therapeutics 17(3): 591-602, 2018

Role of the EZH2 histone methyltransferase as a therapeutic target in cancer. Pharmacology and Therapeutics 165: 26-31, 2017

Inhibition of the histone lysine methyltransferase EZH2 for the treatment of cancer. Current Topics in Medicinal Chemistry 15(8): 714-719, 2015

Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Molecular Cell 49(1): 80-93, 2013

Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. Journal of Gastroenterology and Hepatology 26(1): 19-27, 2011

The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells. Oncotarget 8(40): 68557-68570, 2017

Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322(5908): 1695-1699, 2009

Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer. Oncotarget 8(25): 40402-40411, 2017